Click on image to view larger version.

Figure 3 Infarct size, expressed as a percentage of myocardial risk zone (A), and post-ischemic release of creatine phosphokinase (CPK) (B) in ischemic/reperfused (I/R) control (Ctrl) hearts and hearts exposed to I/R, following ex vivo and in vivo treatment with either minocycline (Mnc) or tetracycline (Tcn). Data are expressed as mean ± SD. ***p < 0.001 versus non-ischemic control hearts. Infarcted areas, assessed by triphenyl-tetrazolium chloride exclusion, in I/R control (C) and in vivo minocycline-treated (D) hearts. The corresponding color-enhanced images (white = infarcted area; green = area at risk; red = non-ischemic zone) are depicted in E (Ctrl hearts) and F (Mnc-treated hearts), respectively. Percentages of TUNEL (G) and cleaved active caspase-3 (C3) (H) positive endothelial cells (EC) and cardiac myocytes (CM) in control hearts exposed or unexposed to I/R, and in I/R hearts pretreated ex vivo and in vivo with either Mnc or Tcn. Values are averages of three independent experiments ±SD. ***p < 0.001 vs. ischemic Ctrl hearts.